Serum creatine kinase is elevated in patients with Parkinson's disease: a case controlled study

2003 ◽  
Vol 9 ◽  
pp. 43-46 ◽  
Author(s):  
Hideki Takubo ◽  
Satoe Shimoda-Matsubayashi ◽  
Yoshikuni Mizuno
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Creatine Kinase ◽  
Serum Creatine Kinase ◽  
Controlled Study

A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease

Neurology ◽  
1995 ◽  
Vol 45 (Issue 3, Supplement 3) ◽  
pp. S22-S27 ◽  
Author(s):  
G. Pezzoli ◽  
E. Martignoni ◽  
C. Pacchetti ◽  
V. Angeleri ◽  
P. Lamberti ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Controlled Study

Parkinson's disease Improved function with GMl ganglioside treatment in a randomized placebo-controlled study

Neurology ◽  
1998 ◽  
Vol 50 (6) ◽  
pp. 1630-1636 ◽  
Author(s):  
J. S. Schneider ◽  
D. P. Roeltgen ◽  
E. L. Mancall ◽  
J. Chapas-Crilly ◽  
D. S. Rothblat ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Controlled Study ◽  
Improved Function

Deep brain stimulation and cognitive functions in Parkinson's disease: A three-year controlled study

2009 ◽  
Vol 24 (11) ◽  
pp. 1621-1628 ◽  
Author(s):  
Roberta Zangaglia ◽  
Claudio Pacchetti ◽  
Chiara Pasotti ◽  
Francesca Mancini ◽  
Domenico Servello ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Deep Brain Stimulation ◽  
Brain Stimulation ◽  
Cognitive Functions ◽  
Controlled Study ◽  
Deep Brain

Placebo-controlled study of rTMS for the treatment of Parkinson's disease

2005 ◽  
Vol 21 (3) ◽  
pp. 325-331 ◽  
Author(s):  
Mikhail P. Lomarev ◽  
Sulada Kanchana ◽  
William Bara-Jimenez ◽  
Meena Iyer ◽  
Eric M. Wassermann ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Controlled Study

A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease

1998 ◽  
Vol 13 (5) ◽  
pp. 782-787 ◽  
Author(s):  
Richard B. Dewey ◽  
Demetrius M. Maraganore ◽  
J. Eric Ahlskog ◽  
Joseph Y. Matsumoto
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Rescue Agent

scholarly journals Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort

2017 ◽  
Vol 89 (1) ◽  
pp. 78-88 ◽  
Author(s):  
Tanya Simuni ◽  
Chelsea Caspell-Garcia ◽  
Christopher S Coffey ◽  
Daniel Weintraub ◽  
Brit Mollenhauer ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rating Scale ◽  
De Novo ◽  
Controlled Study ◽  
Motor Symptoms ◽  
Biological Variables ◽  
Significant Difference ◽  
Non Motor Symptoms ◽  
Updrs Part

ObjectiveTo examine the baseline prevalence and longitudinal evolution in non-motor symptoms (NMS) in a prospective cohort of, at baseline, patients with de novo Parkinson’s disease (PD) compared with healthy controls (HC).MethodsParkinson’s Progression Markers Initiative (PPMI) is a longitudinal, ongoing, controlled study of de novo PD participants and HC. NMS were rated using the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part I score and other validated NMS scales at baseline and after 2 years. Biological variables included cerebrospinal fluid (CSF) markers and dopamine transporter imaging.Results423 PD subjects and 196 HC were enrolled and followed for 2 years. MDS-UPDRS Part I total mean (SD) scores increased from baseline 5.6 (4.1) to 7.7 (5.0) at year 2 in PD subjects (p<0.001) versus from 2.9 (3.0) to 3.2 (3.0) in HC (p=0.38), with a significant difference between the groups (p<0.001). In the multivariate analysis, higher baseline NMS score was associated with female sex (p=0.008), higher baseline MDS-UPDRS Part II scores (p<0.001) and more severe motor phenotype (p=0.007). Longitudinal increase in NMS severity was associated with the older age (0.008) and lower CSF Aβ1–42 (0.005) at baseline. There was no association with the dose or class of dopaminergic therapy.ConclusionsThis study of NMS in early PD identified clinical and biological variables associated with both baseline burden and predictors of progression. The association of a greater longitudinal increase in NMS with lower baseline Aβ1–42 level is an important finding that will have to be replicated in other cohorts.Trial registrationClinicalTrials.gov identifier: NCT01141023.

Sign in / Sign up

Export Citation Format

Share Document